Masaru Kubota
Kanagawa, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
An optimal output and electrode configuration for evaluating tissue transmurality - a preclinical study.
Journal: Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
Published: March 27, 2026
Referential equations for pulmonary diffusing capacity generated from the Japanese population using the Lambda, Mu, or Sigma method and their comparisons with prior referential equations.
Journal: Respiratory investigation
Published: June 02, 2023
The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer.
Journal: Oncology
Published: August 17, 2022
Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring BRAF V600E Mutation.
Journal: OncoTargets and therapy
Published: July 10, 2022
A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Journal: Cancer management and research
Published: September 22, 2021
Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer.
Journal: Investigational new drugs
Published: April 23, 2020
Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer.
Journal: Cancer management and research
Published: March 26, 2020
Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.
Journal: Investigational new drugs
Published: February 17, 2020
Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
Journal: Thoracic cancer
Published: November 12, 2019
Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study.
Journal: Cancer management and research
Published: February 28, 2019
Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study.
Journal: Thoracic cancer
Published: January 04, 2019
Last Updated: 09/26/2026